Ex vivo gene transferring of human dimethylarginine dimethylaminohydrolase-2 improved endothelial dysfunction in diabetic rat aortas and high glucose-treated endothelial cells

Atherosclerosis

Volumn 209, Issue 1, 2010, Pages 66-73

  Lu, Chang Wu ^a   Guo, Zheng ^a   Feng, Mei ^a   Wu, Zhong Zu ^a   He, Zhi Min ^a   Xiong, Yan ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Asymmetric dimethylarginine; Diabetes mellitus; Dimethylarginine dimethylaminohydrolase; Endothelial dysfunction; Gene transferring

Indexed keywords

ADENOVIRUS VECTOR; DIMETHYLARGININASE; DIMETHYLARGININASE 2; GLUCOSE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ENDOTHELIUM CELL; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME REPRESSION; EX VIVO STUDY; GENE CONSTRUCT; GENE OVEREXPRESSION; GENE TRANSFER; HYPERGLYCEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RAT; RISK FACTOR; SPRAGUE DAWLEY RAT; STREPTOZOCIN DIABETES; VASCULAR ENDOTHELIUM; VASODILATATION;

AMIDOHYDROLASES; ANIMALS; AORTA; ARGININE; DIABETES MELLITUS; DIABETES MELLITUS, EXPERIMENTAL; ENDOTHELIUM, VASCULAR; GENE TRANSFER TECHNIQUES; GLUCOSE; HUMANS; HYPERGLYCEMIA; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 77049100020     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.08.035     Document Type: Article

References (29)

1. Wild S., Roglic G., Green A., Sicree R., and King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004) 1047-1053
2. Farhangkhoee H., Khan Z.A., Kaur H., et al. Vascular endothelial dysfunction in diabetic cardiomyopathy: pathogenesis and potential treatment targets. Pharmacol Ther 111 (2006) 384-399
3. Cooke J.P., and Tsao P.S. Arginine: a new therapy for atherosclerosis?. Circulation 95 (1997) 311-312
4. Xiong Y., Lu R., Li Y.J., and Deng H.W. Elevation of an endogenous inhibitor of nitric oxide synthase in diabetic rat serum. Zhongguo Yao Li Xue Bao 18 (1997) 511-514
5. Lin K.Y., Ito A., Asagami T., et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 106 (2002) 987-992
6. Masuda H., Goto M., Tamaoki S., and Azuma H. Accelerated intimal hyperplasia and increased endogenous inhibitors for NO synthesis in rabbits with alloxan-induced hyperglycaemia. Br J Pharmacol 126 (1999) 211-218
7. Stuhlinger M.C., Abbasi F., Chu J.W., et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 287 (2002) 1420-1426
8. Fard A., Tuck C.H., Donis J.A., et al. Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 20 (2000) 2039-2044
9. Xiong Y., Fu Y.F., Fu S.H., and Zhou H.H. Elevated levels of the serum endogenous inhibitor of nitric oxide synthase and metabolic control in rats with streptozotocin-induced diabetes. J Cardiovasc Pharmacol 42 (2003) 191-196
10. Xiong Y., Lei M., Fu S., and Fu Y. Effect of diabetic duration on serum concentrations of endogenous inhibitor of nitric oxide synthase in patients and rats with diabetes. Life Sci 77 (2005) 149-159
11. Boisvert F.M., Cote J., Boulanger M.C., and Richard S. A proteomic analysis of arginine-methylated protein complexes. Mol Cell Proteomics 2 (2003) 1319-1330
12. MacAllister R.J., Parry H., Kimoto M., et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 119 (1996) 1533-1540
13. Leiper J.M., Santa Maria J., Chubb A., et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 343 Pt 1 (1999) 209-214
14. Ito A., Tsao P.S., Adimoolam S., et al. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 99 (1999) 3092-3095
15. Stuhlinger M.C., Tsao P.S., Her J.H., et al. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 104 (2001) 2569-2575
16. Fu Y.F., Xiong Y., and Guo Z. A reduction of endogenous asymmetric dimethylarginine contributes to the effect of captopril on endothelial dysfunction induced by homocysteine in rats. Eur J Pharmacol 508 (2005) 167-175
17. Yin Q.F., Fu S.H., He P., and Xiong Y. Dimethylarginine dimethylaminohydrolase inhibition and asymmetric dimethylarginine accumulation contribute to endothelial dysfunction in rats exposed to glycosylated protein: effects of aminoguanidine. Atherosclerosis 190 (2007) 53-61
18. Xiong Y., Collins Q.F., An J., et al. p38 mitogen-activated protein kinase plays an inhibitory role in hepatic lipogenesis. J Biol Chem 282 (2007) 4975-4982
19. Lu C.W., Xiong Y., and He P. Dimethylarginine dimethylaminohydrolase-2 overexpression improves impaired nitric oxide synthesis of endothelial cells induced by glycated protein. Nitric Oxide 16 (2007) 94-103
20. Monsalve E., Oviedo P.J., Garcia-Perez M.A., et al. Estradiol counteracts oxidized LDL-induced asymmetric dimethylarginine production by cultured human endothelial cells. Cardiovasc Res 73 (2007) 66-72
21. Dayal S., Rodionov R.N., Arning E., et al. Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia. Am J Physiol Heart Circ Physiol 295 (2008) H816-H825
22. Sorrenti V., Mazza F., Campisi A., et al. High glucose-mediated imbalance of nitric oxide synthase and dimethylarginine dimethylaminohydrolase expression in endothelial cells. Curr Neurovasc Res 3 (2006) 49-54
23. Chen Y., Park S., Li Y., et al. Alterations of gene expression in failing myocardium following left ventricular assist device support. Physiol Genomics 14 (2003) 251-260
24. Wakino S., Hayashi K., Tatematsu S., et al. Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertens Res 28 (2005) 255-262
25. Wang D., Gill P.S., Chabrashvili T., et al. Isoform-specific regulation by N(G),N(G)-dimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endothelium-derived relaxing factor/NO. Circ Res 101 (2007) 627-635
26. Hasegawa K., Wakino S., Tatematsu S., et al. Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylarginie dimethylaminohydrolase 2. Circ Res 101 (2007) e2-10
27. Achan V., Tran C.T., Arrigoni F., et al. all-trans-Retinoic acid increases nitric oxide synthesis by endothelial cells: a role for the induction of dimethylarginine dimethylaminohydrolase. Circ Res 90 (2002) 764-769
28. Pullamsetti S., Kiss L., Ghofrani H.A., et al. Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. FASEB J 19 (2005) 1175-1177
29. Noyman I., Marikovsky M., Sasson S., et al. Hyperglycemia reduces nitric oxide synthase and glycogen synthase activity in endothelial cells. Nitric Oxide 7 (2002) 187-193